Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies designed to treat cancers driven by specific oncogenic mutations, including mutant KRAS, BRAF, and TP53. The company uses a proprietary Amphiphile technology platform that delivers immunotherapeutic payloads to lymph nodes to enhance T cell activation and generate durable anti-tumor immune responses. Elicio's lead program, ELI-002, targets multiple common KRAS mutations present across pancreatic, colorectal, and lung cancers, offering an off-the-shelf therapeutic approach that eliminates delays and costs associated with personalized manufacturing. The company generates revenue potential through product sales following regulatory approval and milestone payments and royalties from licensing partnerships, particularly for applications in CAR-T and TCR-T therapies.